{
    "clinical_study": {
        "@rank": "137888", 
        "arm_group": [
            {
                "arm_group_label": "SierraSil", 
                "arm_group_type": "Experimental", 
                "description": "SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine whether supplementation with SierraSil can improve\n      anaerobic power and reduce muscle fatigue in a group of well-trained athletes.\n\n      A secondary purpose is to examine the effect of SierraSil on the severity of delayed onset\n      muscle soreness."
        }, 
        "brief_title": "SierraSil as an Ergogenic Aid to Performance in Athletes", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Muscle Power", 
            "Muscle Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": "Fatigue"
        }, 
        "detailed_description": {
            "textblock": "This is a double blind, crossover, pilot study that will examine the effect of SierraSil\n      supplementation on the determinants of human performance. Anaerobic capacity, muscle\n      fatigue, the severity of delayed onset muscle soreness (DOMS) and markers of inflammation\n      will be measured before and after 3 weeks of supplementation with SierraSil or placebo.\n      There will be a 3 week washout period prior to the crossover to ensure SierraSil\n      supplementation has no residual effect."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  no contraindications to strenuous exercise\n\n        Exclusion Criteria:\n\n          -  muscle or joint injury\n\n          -  taking any form of anti-inflammatory or pain medication\n\n          -  females due to the variability that might be introduced due to the phases of the\n             menstrual cycle"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932281", 
            "org_study_id": "1300304"
        }, 
        "intervention": [
            {
                "arm_group_label": "SierraSil", 
                "description": "SierraSil is a natural, mineral supplement currently used to improve joint health and function.", 
                "intervention_name": "SierraSil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Sugar pill manufactured to mimic SierraSil 667 mg capsule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Central Nervous System Stimulants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "muscle power", 
            "muscle fatigue", 
            "SierraSil"
        ], 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "contact": {
                "email": "diana.jespersen@ubc.ca", 
                "last_name": "Diana K Jespersen", 
                "phone": "604 822 6755"
            }, 
            "facility": {
                "address": {
                    "city": "Vancouver", 
                    "country": "Canada", 
                    "state": "British Columbia", 
                    "zip": "V6T 1Z3"
                }, 
                "name": "University of British Columbia"
            }, 
            "investigator": {
                "last_name": "Donald C. McKenzie, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "SierraSil as an Ergogenic Aid to Performance in Athletes", 
        "overall_contact": {
            "email": "diana.jespersen@ubc.ca", 
            "last_name": "Diana K Jespersen", 
            "phone": "604 822 6755"
        }, 
        "overall_official": {
            "affiliation": "University of British Columbia", 
            "last_name": "Donald C. McKenzie, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in total anaerobic capacity", 
            "safety_issue": "No", 
            "time_frame": "change from baseline at 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of British Columbia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of British Columbia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}